William J Anderson1, Brian J Lipworth1, Sushma Rekhraj1, Allan D Struthers1, Jacob George2. 1. Centre for Cardiovascular and Lung Biology, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland. 2. Centre for Cardiovascular and Lung Biology, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland. Electronic address: j.george@dundee.ac.uk.
Abstract
BACKGROUND: COPD is associated with significant cardiovascular mortality. Left ventricular hypertrophy (LVH) is a pivotal cardiovascular risk factor. The prevalence of LVH in COPD is currently unknown. METHODS: We performed a pilot study of 93 normoxemic patients with COPD and 34 control subjects. Patients underwent echocardiography to measure left ventricular (LV) dimensions, ECG, measurement of serum B-type natriuretic peptide (BNP) levels, and 24-h BP recording. Spirometry and oxygen saturations were also recorded. RESULTS: The oxygen saturations of patients with COPD were normal, at 96.5% (95% CI, 96.1%-97.0%), with a mean FEV(1) of 70.0% predicted (95% CI, 65.2%-74.8%). A total of 30.1% of patients with COPD met the echocardiographic criteria for LVH based on LV mass index, with more LVH in female patients than in male patients (43.2% vs 21.4%, P = .02). The LV mass index in patients with COPD was 96.2 g/m(2) (95% CI, 90.1-102.7 g/m(2)) vs 82.9 g/m(2) (95% CI, 75.8-90.6 g/m(2)) in control subjects ( P = .017). The LV mass index remained high in patients with COPD in the absence of a hypertension history (94.5 g/m(2) vs 79.9 g/m(2), P = .015) and with 24-h systolic BP <135 mm Hg (96.7 g/m(2) vs 82.5 g/m(2), P = .024). The LV ejection fraction (mean = 63.4%) and BNP (mean = 28.7 pg/mL) were normal in patients with COPD. The mean 24-h BP was normal in patients with COPD, at 125/72 mm Hg. ECG was less sensitive for detecting LVH than was echocardiography. CONCLUSION: LVH with normal LV ejection fraction and BNP levels was present in a significant proportion of normotensive, normoxemic patients with COPD, especially female patients. Clinical trials are, therefore, indicated to evaluate treatments to regress LVH in patients with COPD.
BACKGROUND:COPD is associated with significant cardiovascular mortality. Left ventricular hypertrophy (LVH) is a pivotal cardiovascular risk factor. The prevalence of LVH in COPD is currently unknown. METHODS: We performed a pilot study of 93 normoxemic patients with COPD and 34 control subjects. Patients underwent echocardiography to measure left ventricular (LV) dimensions, ECG, measurement of serum B-type natriuretic peptide (BNP) levels, and 24-h BP recording. Spirometry and oxygen saturations were also recorded. RESULTS: The oxygen saturations of patients with COPD were normal, at 96.5% (95% CI, 96.1%-97.0%), with a mean FEV(1) of 70.0% predicted (95% CI, 65.2%-74.8%). A total of 30.1% of patients with COPD met the echocardiographic criteria for LVH based on LV mass index, with more LVH in female patients than in male patients (43.2% vs 21.4%, P = .02). The LV mass index in patients with COPD was 96.2 g/m(2) (95% CI, 90.1-102.7 g/m(2)) vs 82.9 g/m(2) (95% CI, 75.8-90.6 g/m(2)) in control subjects ( P = .017). The LV mass index remained high in patients with COPD in the absence of a hypertension history (94.5 g/m(2) vs 79.9 g/m(2), P = .015) and with 24-h systolic BP <135 mm Hg (96.7 g/m(2) vs 82.5 g/m(2), P = .024). The LV ejection fraction (mean = 63.4%) and BNP (mean = 28.7 pg/mL) were normal in patients with COPD. The mean 24-h BP was normal in patients with COPD, at 125/72 mm Hg. ECG was less sensitive for detecting LVH than was echocardiography. CONCLUSION: LVH with normal LV ejection fraction and BNP levels was present in a significant proportion of normotensive, normoxemic patients with COPD, especially female patients. Clinical trials are, therefore, indicated to evaluate treatments to regress LVH in patients with COPD.
Authors: Harjit Chahal; Susan R Heckbert; R Graham Barr; David A Bluemke; Aditya Jain; Mohammadali Habibi; Alvaro Alonso; Richard Kronmal; David R Jacobs; Joao A C Lima; Karol E Watson; Kiang Liu; Lewis J Smith; Philip Greenland Journal: Am J Cardiol Date: 2015-03-24 Impact factor: 2.778
Authors: Philip M Short; William J Anderson; Douglas H J Elder; Allan D Struthers; Brian J Lipworth Journal: Lung Date: 2015-03-29 Impact factor: 2.584
Authors: Paulo R Mendes; Tatiana A Kiyota; José A Cipolli; Roberto Schreiber; Layde R Paim; Vera R Bellinazzi; José R Matos-Souza; Andrei C Sposito; Wilson Nadruz Journal: Hypertens Res Date: 2014-11-27 Impact factor: 3.872
Authors: Nathaniel M Hawkins; Amit Khosla; Sean A Virani; John J V McMurray; J Mark FitzGerald Journal: BMC Pulm Med Date: 2017-01-10 Impact factor: 3.317
Authors: Jonathan R Weir-McCall; Patrick Sk Liu-Shiu-Cheong; Allan D Struthers; Brian J Lipworth; J Graeme Houston Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-05-28
Authors: Radostina Vl Cherneva; Mariana V Gospodinova; Stefan V Denchev; Rosen B Petkov; Dimitar E Kostadinov; Zheina Vl Cherneva Journal: Croat Med J Date: 2019-10-31 Impact factor: 1.351
Authors: Paul Leong; Martin I MacDonald; Paul T King; Christian R Osadnik; Brian S Ko; Shane A Landry; Kais Hamza; Ahilan Kugenasan; John M Troupis; Philip G Bardin Journal: ERJ Open Res Date: 2021-02-08
Authors: Rafael Golpe; Alfonso Mateos-Colino; Ana Testa-Fernández; Marta Pena-Seijo; Manuel Rodríguez-Enríquez; Carlos González-Juanatey; Francisco J Martín-Vázquez; Antonio Pose-Reino; Nuria Domínguez-Pin; Nuria Garnacho-Gayarre; Luis A Pérez-de-Llano Journal: PLoS One Date: 2016-06-30 Impact factor: 3.240